WPG Advisers’s CG Oncology CGON Stock Holding History

WPG Advisers’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71	Hold	1	–	–	﹤0.01%	1535
2026 Q1	$68	Hold	1	–	–	﹤0.01%	1463
2025 Q4	$42	Buy	+1	New	+$41	﹤0.01%	1475

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPG Advisers's CGON Position: Q2 2026 in Review

WPG Advisers held its CG Oncology (CGON) position steady in Q2 2026 at 1 share worth $71. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

WPG Advisers first reported a position in CGON in Q4 2025 and has held it in 3 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

WPG Advisers held 1 share of CG Oncology worth $71 as of Q2 2026.
WPG Advisers left its CG Oncology share count unchanged in Q2 2026.
CG Oncology made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #1535 holding.
WPG Advisers first reported a position in CG Oncology in Q4 2025 and has held it in 3 quarters since.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.